MLCK

MLCK製品

• All (11)
• MLCK阻害剤 (6)
• MLCK拮抗剤(1)
• MLCKモジュレータ(1)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1573	Fasudil HCl	Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.	Stem Cell Res Ther, 2025, 16(1):597 Transl Oncol, 2025, 51:102209 J Immunother Cancer, 2024, 12(11)e009805
S8388	ML-7 HCl	ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.	Proc Natl Acad Sci U S A, 2025, 122(8):e2421717122 Cell Mol Life Sci, 2025, 82(1):201 Commun Biol, 2025, 8(1):607
S8861	Mavacamten (MYK-461)	Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.	Eur Heart J, 2025, ehaf813 Circ Res, 2025, S1525-0016(25)00760-9. Circulation, 2023, 147(25):1919-1932
S6847	ML-9 HCl	ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). ML-9 HCl is also a potent inhibitor of Ca2+-permeable channels. ML-9 HCl is a lysosomotropic agent targeting autophagy and cell death.	Cell Mol Life Sci, 2025, 82(1):201 PLoS Pathog, 2023, 19(3):e1011295 J Mol Endocrinol, 2019, 63(3):199-213
F0769	Myosin IIb Antibody [L17J19]	Myosin IIb Rabbit mAb recognizes endogenous levels of total myosin IIb protein.
F0485New	Myosin Light Chain 2 Antibody [J14M12]
F1437	Myosin IIc Antibody [D7M19]
S3699	2,3-Butanedione-2-monoxime	2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
E5817New	Sevasemten	Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.
E2506	A-3 hydrochloride	A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S2964	HA-100 dihydrochloride	HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.	Adv Sci (Weinh), 2024, 11(4):e2304987
S1573	Fasudil HCl	Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.	Stem Cell Res Ther, 2025, 16(1):597 Transl Oncol, 2025, 51:102209 J Immunother Cancer, 2024, 12(11)e009805
S8388	ML-7 HCl	ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.	Proc Natl Acad Sci U S A, 2025, 122(8):e2421717122 Cell Mol Life Sci, 2025, 82(1):201 Commun Biol, 2025, 8(1):607
S6847	ML-9 HCl	ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). ML-9 HCl is also a potent inhibitor of Ca2+-permeable channels. ML-9 HCl is a lysosomotropic agent targeting autophagy and cell death.	Cell Mol Life Sci, 2025, 82(1):201 PLoS Pathog, 2023, 19(3):e1011295 J Mol Endocrinol, 2019, 63(3):199-213
S3699	2,3-Butanedione-2-monoxime	2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
E5817New	Sevasemten	Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.
S2964	HA-100 dihydrochloride	HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.	Adv Sci (Weinh), 2024, 11(4):e2304987
E2506	A-3 hydrochloride	A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S8861	Mavacamten (MYK-461)	Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.	Eur Heart J, 2025, ehaf813 Circ Res, 2025, S1525-0016(25)00760-9. Circulation, 2023, 147(25):1919-1932
F0485New	Myosin Light Chain 2 Antibody [J14M12]
E5817New	Sevasemten	Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy.